Business
Biote runs a practice-building platform for hormone optimization, serving Biote-certified practitioners with education, software, inventory tools, product information, and dietary supplements.
Biote's FY2025 net income rose sharply, but revenue and FCF declined, equity stayed negative, and leadership churn adds caution.
The read at a glance✓ Audited against SEC data
- Business mix — Hormone optimization platformNote
- Revenue — $192.2M, -2.5%Watch
- Net income — $27.0M, +756.7%OK
- FCF — $30.2M, -22.2%Watch
- Debt — $103.1M, -5.7%OK
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman grey; Beneish clean; EQ safeNote
Where the revenue comes from
Fiscal 2025, as biote Corp. reports it. History and quarterly detail are in the app.
- Product Revenue$186.9M
- Pellet Procedures Product Revenue$137.0M
- Dietary Supplements$42.9M
- Service Revenue$5.3M
- Disposable Trocars Product Revenue$4.9M
Leadership changes
From biote Corp.'s own filings, the day they're filed.
- Bret Christensen · Chief Executive Officer · departureeff. 2026-06-08
- Marc Beer · Chairman · appointmenteff. 2026-06-08
- Robert Peterson · Chief Executive Officer · departureeff. 2026-06-08
Latest filings
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-18
- 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about biote Corp., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.